Cellectis S.A. (CLLS): Price and Financial Metrics
Cellectis S.A. (CLLS)
Today's Latest Price: $17.85 USD
Updated Sep 25 4:00pm
Add CLLS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 233 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CLLS Stock Summary
- With a price/sales ratio of 8.7, Cellectis SA has a higher such ratio than 85.14% of stocks in our set.
- With a year-over-year growth in debt of 69.94%, Cellectis SA's debt growth rate surpasses 84.24% of about US stocks.
- Revenue growth over the past 12 months for Cellectis SA comes in at 299.44%, a number that bests 97.83% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Cellectis SA, a group of peers worth examining would be ZYME, BLUE, APTX, NKTR, and ARVN.
- Visit CLLS's SEC page to see the company's official filings. To visit the company's web site, go to www.cellectis.com.
CLLS Stock Price Chart Technical Analysis Charts
CLLS Price/Volume Stats
| Current price | $17.85 | 52-week high | $21.97 |
| Prev. close | $17.35 | 52-week low | $7.32 |
| Day low | $17.26 | Volume | 94,184 |
| Day high | $17.86 | Avg. volume | 168,345 |
| 50-day MA | $17.77 | Dividend yield | N/A |
| 200-day MA | $16.04 | Market Cap | 758.02M |
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
Loading social stream, please wait...